Skip to main content

11-04-2010 | Bone health | Article

CTx valuable tool for assessing postmenopausal osteoporotic patients


Free abstract

MedWire News: Increased serum C-terminal telopeptide of type I collagen (CTx) is associated with decreased bone mineral density (BMD) and may therefore be a valuable tool in the assessment of postmenopausal osteoporotic patients, say researchers from Pakistan.

“Bone turnover markers can prove beneficial when BMD changes are too small to be utilized clinically, particularly within the first 6 months after antiresorptive therapy initiation,” note Mehreen Lateef (Pakistan Council of Scientific and Industrial Research Laboratories Complex, Karachi) and colleagues.

In the present study, Lateef and team investigated the significance of serum osteocalcin, a marker of bone formation, and CTx, a marker of bone resorption, in evaluating osteoporotic patients and explored their relationship with BMD.

They measured BMD at the calcaneous by peripheral ultrasound bone densitometery in 50 premenopausal women (mean age 31 years), 50 postmenopausal women without osteoporosis (mean age 54 years) and 50 postmenopausal women with osteoporosis (mean age 59 years) and correlated their findings with serum levels of osteocalcin, CTx, and calcium.

The researchers found that serum CTx levels were significantly higher in postmenopausal women with and without osteoporosis than in premenopausal women and that CTx correlated positively with age.

In contrast, there was a negative correlation between CTx and BMD in postmenopausal women with and without osteoporosis indicating increased bone resorption in these individuals.

A significant negative correlation was also observed between age and BMD. Postmenopausal women, with and without osteoporosis, had significantly lower BMD than premenopausal women, indicating increased bone loss with aging and menopause.

Osteocalcin did not correlate with BMD or age, which suggests “heterogeneity of osteocalcin fragments in serum that limits its significance in the evaluation of osteoporosis,” say the researchers. However, a significant positive correlation was found between osteocalcin and CTx.

“In the clinical situation, bone markers are easier to obtain and less expensive than bone mass measurements,” write Lateef and co-authors in the journal Osteoporosis International.

They conclude: “[CTx] appears to be a significant determinant of bone loss and may be used as a valuable tool in the assessment of postmenopausal osteoporotic patients.”

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Laura Dean

Related topics